Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,117.28 -4.08 (-0.36%)
Streaming Delayed Price Updated: 3:58 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Eli Lilly Could Swing $65.9 Billion After Earnings ↗
Earnings coming Wed with varying volatility levels. Benzinga Pro selected list incl. relatively muted setups to double-digit swings. Top pick Eli Lilly. 
Via Benzinga
News headline image
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings ↗
Eli Lilly investors may be eyeing potential gains from the company’s annual dividend yield of 0.62% ($6.92 a year). 
Via Benzinga
News headline image
Eli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started? ↗
Eli Lilly's key catalyst for 2027 could positively affect price action sooner than you think. 
Via The Motley Fool
News headline image
Amazon and Microsoft Gained a Combined $1.04 Trillion in Market Cap in 2 Days, While Apple and Meta Platforms Lost $510 Billion. Meet the Vanguard ETF That's Built for This Exact Market. ↗
With volatility heating up, some investors may prefer the straightforward approach of the Vanguard Mega Cap Growth ETF. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
Eli Lilly (NYSE:LLY) Stands Out as a High-Growth Momentum Leader ↗
Via Chartmill
News headline image
What To Expect From Eli Lilly’s (LLY) Q2 Earnings
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results this Wednesday morning. Here’s what investors should know. Eli Lilly beat analys... 
Via StockStory
Topics Artificial Intelligence
News headline image
Inspire Medical Systems Q2 Earnings Call Highlights ↗
Inspire Medical Systems (NYSE:INSP) reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The... 
Via MarketBeat
Topics Earnings
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Is Eli Lilly Stock Running out of Steam? ↗
The healthcare stock is up over 300% in five years and has a market cap of around $1 trillion. 
Via The Motley Fool
News headline image
Eli Lilly Could Swing Over $76 Billion In Value After Earnings ↗
Earnings season is approaching, and Benzinga Pro has a list of top stocks to watch. Gilead Sciences and Uber Technologies are expected to have significant market moves based on their upcoming earnings... 
Via Benzinga
News headline image
Which Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI? ↗
XBI surged 76% in one year but carries triple the expense ratio and far steeper downside risk. Which fund matches your risk appetite? 
Via The Motley Fool
Topics ETFs
News headline image
Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗
Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors. 
Via The Motley Fool
News headline image
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy? ↗
IBBQ posted the stronger return over the past year, but has also experienced much higher historical volatility than XLV. 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031 ↗
And it will likely be the first company in the sector to get there. 
Via The Motley Fool
News headline image
XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist? ↗
PBE surged 41% in one year but endured a 35% drawdown, while XLV's diversified approach delivered steadier gains with half the volatility. 
Via The Motley Fool
Topics ETFs
News headline image
Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit? ↗
FHLC holds 334 positions versus IYH's 100, yet both delivered similar five-year returns despite their structural differences. 
Via The Motley Fool
Topics ETFs
News headline image
Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip? ↗
With the stock near a 5-year low, is it worth a look? 
Via The Motley Fool
News headline image
Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore. ↗
The global market for obesity drugs is soaring, yet Lilly has a dominant market share. 
Via The Motley Fool
News headline image
XLV vs. IHE: Which Healthcare ETF Is the Better Buy? ↗
IHE's pharma-focused portfolio delivered higher returns over the past year, while XLV offers a broader healthcare focus with a much lower expense ratio. 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels ↗
Wegovy and Zepbound makers Novo Nordisk and Eli Lilly faced pressure. 
Via Investor's Business Daily
News headline image
Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH? ↗
FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings. 
Via The Motley Fool
Topics ETFs
News headline image
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗
There are other reasons to pay attention to Viking Therapeutics. 
Via The Motley Fool
News headline image
VHT vs. PBE: Which Health Care ETF Is the Better Buy? ↗
PBE delivered the better return over the past year, but has experienced greater historical volatility. VHT's more diversified portfolio and rock-bottom fees offer investors a steadier, lower-cost... 
Via The Motley Fool
Topics ETFs
News headline image
Jim Cramer: Eli Lilly Is A 'Good Company,' But Doesn't 'Really Care For' This Quantum Stock ↗
CNBC's Mad Money Lightning Round: Cramer says Astera Labs (ALAB) is a buy, but doesn't care for Rigetti Computing (RGTI). Eli Lilly (LLY) is a classic own, don't trade. MakeMyTrip (MMYT) coverage... 
Via Benzinga
News headline image
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗
But is that performance sustainable? 
Via The Motley Fool
News headline image
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold ↗
They may profit from the rapidly growing GLP-1 market in very different ways. 
Via The Motley Fool
News headline image
State Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio? ↗
FBT delivered 48.5% returns over one year but carries a 0.55% expense ratio and experiences greater volatility. XLV offers lower costs, with an 0.08% expense ratio, as well as broader diversification... 
Via The Motley Fool
Topics ETFs
News headline image
Forget Weight Loss Drugs: Here's Another Reason to Buy Eli Lilly Stock ↗
Lilly's pipeline is on track to pick up a handful of interesting new programs. 
Via The Motley Fool
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients ↗
Will this pharma company become a new leader in the weight loss market? 
Via The Motley Fool
News headline image
Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth ↗
Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.